National Academies Press: OpenBook

Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism (2001)

Chapter: Appendix A: Januaray 11, 2001 - Meeting Agenda

« Previous: Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism
Suggested Citation:"Appendix A: Januaray 11, 2001 - Meeting Agenda." Institute of Medicine. 2001. Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism. Washington, DC: The National Academies Press. doi: 10.17226/10101.
×

Page 71

APPENDIX A

January 11, 2001
Meeting Agenda

IMMUNIZATION SAFETY REVIEW COMMITTEE ORGANIZATIONAL MEETING

National Academies Building

2101 Constitution Avenue, NW

Washington, DC

9:00–9:15 a.m.

Welcome and Introductions

Marie McCormick, M.D., Sc.D., Chair, Immunization Safety Review Committee

9:15–9:45 a.m.

Presentation of the Charge to the Committee

Martin G. Myers, M.D., Director, National Vaccine Program Office, Department of Health and Human Services

Walter A. Orenstein, M.D., Director, National Immunization Program, Centers for Disease Control and Prevention

Carole A. Heilman, Ph.D., Director, Division of Microbiology and Infectious Diseases, National Institute for Allergies and Infectious Diseases, National Institutes of Health

9:45–10:45 a.m.

Perspectives on Vaccine Safety

The Honorable Henry Waxman, Ranking minority member, Committee on Government Reform, United States House of Representatives

The Honorable Dave Weldon, United States House of Representatives

Suggested Citation:"Appendix A: Januaray 11, 2001 - Meeting Agenda." Institute of Medicine. 2001. Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism. Washington, DC: The National Academies Press. doi: 10.17226/10101.
×

Page 72

 

S. Elizabeth Clay, Professional Staff Member, Committee on Government Reform, United States House of Representatives

11:00–11:30 a.m.

Perspectives on Vaccine Safety

Louis Cooper, M.D., Professor of Pediatrics, Columbia University, and Vice-President, American Academy of Pediatrics

11:30 a.m.–12:00 p.m.

Perspectives on Vaccine Safety

Barbara Loe Fisher, President and Co-Founder, National Vaccine Information Center

12:00–12:30 p.m.

Current Vaccine Safety Data Sources

Robert T. Chen, M.D., M.A., Chief, Vaccine Safety and Development Activity, National Immunization Program, Centers for Disease Control and Prevention

1:30–2:00 p.m.

Causality Assessments in IOM Vaccine Safety Studies

Richard B. Johnston, Jr., M.D., Professor of Pediatrics, University of Colorado

2:00–2:30 p.m.

Methodological Considerations in Evaluating Evidence

David Tollerud, M.D., M.P.H., Professor, Public Health, Medicine, and Community and Preventive Medicine (EOH), Director, Center for Environmental and Occupational Health, School of Public Health, MCP Hahnemann University

2:30–3:00 p.m.

Decision-Making Under Uncertainty: The Case of Iodine-131

Robert S. Lawrence, M.D., Edyth Schoenrich Professor of Preventive Medicine and Professor of Health Policy, Johns Hopkins University School of Hygiene and Public Health

3:15–3:45 p.m.

Risk Assessment and Management Under Uncertainty: Lessons From Swine Flu and HIV in Blood Products

Michael Stoto, Ph.D., Professor and Chair, Epidemiology & Biostatistics, George Washington University

Suggested Citation:"Appendix A: Januaray 11, 2001 - Meeting Agenda." Institute of Medicine. 2001. Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism. Washington, DC: The National Academies Press. doi: 10.17226/10101.
×

Page 73

3:45–4:15 p.m.

Decision Analysis: Applications to Immunization Policy

Richard Rheingans, Ph.D., Research Assistant Professor, Rollins School of Public Health, Emory University

4:15–4:45 p.m.

Risk Perception and Risk Communication Overview

Baruch Fischhoff, Ph.D., Professor of Social and Decision Sciences and of Engineering and Public Policy, Carnegie Mellon University

4:45–5:00 p.m.

Research in Public Perceptions of Vaccine Safety

Beth Hibbs, R.N., M.P.H., Vaccine Safety and Development Activity, National Immunization Program, Centers for Disease Control and Prevention

5:00–5:30 p.m.

Framework for Considering Issues and Recommendations

Amy Fine, M.P.H., B.S.N., Health Policy/Program Consultant, Washington, DC

5:30–6:00 p.m.

Open Discussion

Suggested Citation:"Appendix A: Januaray 11, 2001 - Meeting Agenda." Institute of Medicine. 2001. Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism. Washington, DC: The National Academies Press. doi: 10.17226/10101.
×

Page 74

Suggested Citation:"Appendix A: Januaray 11, 2001 - Meeting Agenda." Institute of Medicine. 2001. Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism. Washington, DC: The National Academies Press. doi: 10.17226/10101.
×
Page 71
Suggested Citation:"Appendix A: Januaray 11, 2001 - Meeting Agenda." Institute of Medicine. 2001. Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism. Washington, DC: The National Academies Press. doi: 10.17226/10101.
×
Page 72
Suggested Citation:"Appendix A: Januaray 11, 2001 - Meeting Agenda." Institute of Medicine. 2001. Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism. Washington, DC: The National Academies Press. doi: 10.17226/10101.
×
Page 73
Suggested Citation:"Appendix A: Januaray 11, 2001 - Meeting Agenda." Institute of Medicine. 2001. Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism. Washington, DC: The National Academies Press. doi: 10.17226/10101.
×
Page 74
Next: Appendix B: March 8, 2001 - Meeting Agenda »
Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism Get This Book
×
Buy Paperback | $35.00 Buy Ebook | $27.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Immunization is widely regarded as one of the most effective and beneficial tools for protecting the public's health. In the United States, immunization programs have resulted in the eradication of smallpox, the elimination of polio, and the control and near elimination of once-common, often debilitating and potentially life-threatening diseases, including measles, mumps, rubella, diphtheria, pertussis, tetanus, and Haemophilus influenza type b.

Along with the benefits of widespread immunization, however, have come concerns about the safety of vaccines. No vaccine is perfectly safe or effective, and vaccines may lead to serious adverse effects in some instances. Furthermore, if a serious illness is observed after vaccination, it is often unclear whether that sequence is coincidental or causal, and it can be difficult to determine the true nature of the relationship, if any, between the vaccination and the illness. Ironically, the successes of vaccine coverage in the United States have made it more difficult for the public to weigh the benefits and complications of vaccines because the now-controlled diseases and their often-serious risks are no longer familiar. However, because vaccines are so widely used-and because state laws require that children be vaccinated before entering daycare and school, in part to protect others-it is essential that safety concerns be fully and carefully studied.

Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism, the first of a series from the Institute of Medicine (IOM) Immunization Safety Review Committee, presents an assessment of the evidence regarding a hypothesized causal association between the measles-mumps-rubella (MMR) vaccine and autism, an assessment of the broader significance for society of the issues surrounding the MMR-autism hypothesis, and the committee's conclusions and recommendations based on those assessments.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!